NextFin news, On November 13, 2025, the United States Congress passed, and President Donald Trump subsequently signed into law, a government spending bill that includes a provision banning the sale and distribution of hemp-derived tetrahydrocannabinol (THC) products nationwide exceeding 0.4 milligrams of THC per container. This legislation emerges as part of the federal funding package that ended the longest U.S. government shutdown, and it directly targets consumable hemp products such as gummies, drinks, topical salves, and vapes. The move rescinds a regulatory loophole created in the 2018 Farm Bill which had legalized hemp and enabled a rapid growth in low-dose THC products marketed broadly across states including Texas, Minnesota, Illinois, and Colorado.
The provision was championed by Senate Majority Leader Mitch McConnell and other lawmakers advocating for stricter control over intoxicating hemp products, citing concerns over public health risks, underregulated recreational use, and challenges for law enforcement. Key Texas Republicans, including Senator John Cornyn, supported it, while others like Senator Ted Cruz opposed the federal imposition favoring state-level regulation. The ban is scheduled to take effect one year after enactment, offering a window for legal and market adjustments.
This federal mandate starkly contrasts with several states' more permissive regulatory frameworks, where THC levels in hemp products can exceed the new federal cap. For example, Minnesota currently allows up to 5 milligrams of THC per serving, and Minnesota’s hemp industry, led by companies like Surly Brewing, plans to legally challenge the ban. The industry warns the new limit is impractically low and would eliminate approximately 95% of the current market. The U.S. Hemp Roundtable estimates the ban could wipe out the $28.4 billion hemp industry nationwide, threatening over 300,000 American jobs and causing $1.5 billion in lost tax revenues.
Several affected stakeholders have voiced alarm. Veterans, such as those represented by the Texas Department of the Veterans of Foreign Wars, rely heavily on hemp-derived THC products for pain and PTSD symptom management without psychoactive effects. They warn that banning these options could push vulnerable populations back to more harmful substances like opioids or alcohol. Small businesses and farmers foresee a devastating economic impact, with Illinois hemp farmer Stacy describing the legislation as “crushing” her topical product company, and Minnesota brewers predicting closures across the state.
From an economic perspective, this policy reversal disrupts a sector that has seen exponential growth since 2018 due to the initial legalization of hemp and the lack of robust federal regulation. The national hemp-derived THC market, buoyed by consumer interest in wellness, alternative pain relief, and recreational use, has become a lucrative source of jobs and state revenue. The federal limitation to 0.4 mg THC effectively criminalizes most products that have gained marketplace traction and consumer acceptance.
The ban reflects a broader political and regulatory tension between federal and state authorities on cannabis policy. While states have sought to tailor regulations to local preferences and economic needs, the federal government is asserting a uniform standard that some perceive as overly restrictive and contrary to market realities. This federal intervention, enacted via a must-pass spending bill, sidestepped extensive debate, which has drawn criticism from industry advocates and legislators concerned about transparency and stakeholder engagement.
Looking forward, the legislation sets up a complex period of enforcement and legal contestation. The one-year lead time allows companies and lawmakers to explore repeal or mitigation measures, and several states and industry groups are expected to lobby aggressively for amendments or federal regulatory reform. Simultaneously, the ban may trigger a shift in consumer behavior, pushing demand either back to black market channels or alternative hemp products with compliant THC levels, potentially less effective for medical uses.
Furthermore, this development signals an increased federal scrutiny of the cannabis derivative marketplace, with implications for investors, agribusinesses, and retailers nationally. The crackdown may stifle innovation and investment in hemp product formulations that have been catalysts for revenue growth and diversified agricultural economies in many states. Economists and policy analysts will need to monitor ensuing economic ripple effects, including the potential loss of state tax income and the impact on small businesses.
In conclusion, the federal prohibition on hemp-derived THC products above 0.4 milligrams represents a significant retrenchment in U.S. cannabis policy under President Trump’s administration in 2025. Balancing public health concerns with economic vitality and consumer access remains a contentious challenge. The industry’s response, along with evolving legislative dynamics, will shape the future regulatory landscape and economic health of this burgeoning market segment in the years ahead.
According to reports from ABC News and The Texas Tribune, this policy shift poses profound questions about federalism, industry sustainability, and public health priorities in the rapidly evolving sector of hemp-derived cannabinoids.
Explore more exclusive insights at nextfin.ai.
